Wuxi Hebang Biotechnology Co. Ltd.

Main purpose: Evaluate the safety and tolerability of HB1085 after multiple continuous administration in healthy subjects; Evaluate the pharmacokinetic characteristics of different doses of HB1085 after multiple administration in healthy subjects. Secondary purpose: Preliminary evaluation of the pharmacodynamic characteristics of different doses of HB1085 after multiple administration in healthy subjects; Provide a basis for dose selection for subsequent clinical studies of HB1085; Evaluate the immunogenicity of HB1085 after multiple administration in healthy subjects at different doses.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation exenatide injection 10μg (specification: 0.25mg/ml, 2.4ml/vial, 1vial/box; produced and provided by Wuxi Hebang Biotechnology Co., Ltd.) and the reference preparation exenatide injection 10μg (trade name: Byetta; specification: 0.25mg/ml, 2.4ml/vial, 1vial/box; produced by Baxter Pharmaceutical Solutions LLC.; provided by Wuxi Hebang Biotechnology Co., Ltd.) in Chinese healthy subjects in the fasting state, and to evaluate the bioequivalence of the two preparations in the fasting state. Secondary objective: To observe the safety of the test preparation exenatide injection and the reference preparation exenatide injection (Byetta) in Chinese healthy subjects.

Primary objective: To observe the pharmacokinetic characteristics of the experimental drug HB1082 (teriparatide injection) (specification: 20μg:80μL, 2.4mL/vial; manufacturer: Wuxi Hebang Biotechnology Co., Ltd., provider: Wuxi Hebang Biotechnology Co., Ltd.) and the reference drug teriparatide injection (trade name: Futaio; specification: 20μg:80 μL, 2.4mL/vial; manufacturer: Lilly France; provider: Wuxi Hebang Biotechnology Co., Ltd.) in healthy Chinese subjects, and to evaluate the pharmacokinetic similarity of the two preparations. Secondary objective: To compare the safety and tolerability of a single subcutaneous injection of 20μg of the experimental drug HB1082 and the reference drug teriparatide injection (Futaio) in healthy Chinese subjects; to compare the changes in serum calcium concentration after a single subcutaneous injection of 20μg of the experimental drug HB1082 and the reference drug teriparatide injection (Futaio) in healthy Chinese subjects.